On April 13, 2018 VAXIMM AG, a Swiss/German biotech company focused on developing oral T-cell immunotherapies, reported that the Company will participate in several upcoming events in the second quarter of 2018 (Press release, Vaximm, APR 13, 2018, View Source [SID1234525295]).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
AACR (American Association for Cancer Research) Annual Meeting 2018 April 14 – 18, 2018 Chicago, IL, USA
Poster #733 / 18: "Modulating T cell immunity in tumors by targeting PD‑L1 and neoantigens using a live attenuated oral Salmonella platform"
Poster Session: Vaccines 1
Sunday, April 15th, 1:00 PM – 5:00 PM
The poster summarizes the immunogenicity and anti-leukemia efficacy of VAXIMM’s oral T‑cell immunotherapy candidate VXM10 encoding variants of the murine PD-L1 protein. The animal study also describes the systemic immunogenicity of Salmonella-based polyepitope oral vaccines, supporting the design of Salmonella-based neoantigen vaccines.
The abstract is available here.
European Neoantigen Summit 2018
April 24 – 26, 2018
Amsterdam, The Netherlands
Presentation: "Fast and Cost-Effective Oral Delivery Technology of Personalized T-Cell Vaccines Based on a Live Attenuated Bacteria Platform"
Thursday, April 26th, 11:15 AM CEST
Dr. Heinz Lubenau, Chief Operating Officer of VAXIMM, will present the Company’s platform technology based on first-in-class oral T-cell activators using modified attenuated bacteria that can be readily adapted to target a wide range of cancer-related antigens.
Dr. Lubenau also will participate in the panel, "Advancing Manufacturing Practices for Personalized Cancer Vaccines" taking place on Thursday, April 26th at 2:45 PM CEST.
Bio€quity Europe
May 14 – 16, 2018
Ghent, Belgium
Dr. Lubenau will give a corporate presentation on Tuesday, May 15th at 11:40 AM CEST.